Pharmaceuticals Global On demand · 24-48h

Global Postoperative Pain Control Drug Market Strategic Research Report

Global Postoperative Pain Control Drug Market Strategic Rese…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Postoperative Pain Control Drug Market
$5.12B2025
6.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Opioids, NSAIDs, Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs, Others

By Application: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Mallinckrodt Pharmaceuticals (IE), Pfizer (US), Novartis (CH), Eli Lilly (US), Teva Pharmaceutical Industries (IL), Bayer (DE), Pacira BioSciences (US), Trevena (US), Vertex Pharmaceuticals (US), Heron Therapeutics (US), Nanjing Delova Biotech (CN), Jiangsu Nhwa Pharmaceutical (CN)

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 121 pages
Market size 2025
$5.12B
Billion USD
Forecast CAGR
6.3%
2025-2032
Forecast 2032
$7.9B
Projected
영역들
5
Asia Pacific · Latin America · MEA · Europe · North America

개요

Scope of the Report

The global Postoperative Pain Control Drug market size is predicted to grow from US$ 5,120 million in 2025 to US$ 7,744 million in 2032; it is expected to grow at a CAGR of 6.3% from 2026 to 2032.

Postoperative Pain Control Drugs encompass a specialized class of acute-use pharmaceuticals formulated to suppress nociceptive (pain-sensing) signaling pathways following surgical trauma. Historically dominated by central nervous system (CNS) mu-opioid receptor agonists like morphine, fentanyl, and hydromorphone, modern postoperative pain protocols have radically shifted toward multimodal analgesia. This clinical strategy combines lower-dose opioids with diverse non-opioid mechanism families to maximize pain control while mitigating systemic side effects like respiratory depression, postoperative nausea and vomiting (PONV), and long-term dependency.

In 2025, global Postoperative Pain Control Drugs production reached approximately 414.08 million doses, with an average global market price of around US$ 12.64 per dose. And global Postoperative Pain Control Drugs production capacity reached approximately 540 million doses. The average gross margin in this industry reached 42.02%.

The supply chain for postoperative pain control drugs requires stringent chemical synthesis compliance, high-barrier sterile filling facilities, and specialized drug delivery carrier matrices. The upstream supply chain provides the foundational Active Pharmaceutical Ingredients (APIs), key chemical precursors, and advanced multi-phase delivery vehicles. Global life sciences chemical suppliers like Lonza Group and Siegfried Holding AG serve as critical upstream contract development and manufacturing organizations (CDMOs), synthesizing high-purity small molecule APIs under strict Current Good Manufacturing Practice (cGMP) regulations. For extended-release formulations, specialized polymer firms provide the upstream lipid matrices and bioresorbable poly(lactic-co-glycolic acid) (PLGA) microspheres required to encapsulate local anesthetics for multi-day local release. Concurrently, primary packaging giants like West Pharmaceutical Services, Inc. supply the critical upstream components, delivering the passivated elastomeric vial stoppers and sterile, ready-to-fill glass cartridges needed to ensure long-term formulation stability.

Conversely, the downstream supply chain spans specialty pharmaceutical innovators, generic drug manufacturers, sterile compounding operators, and institutional healthcare buyers. Major acute care pharmaceutical developers—such as Pacira BioSciences, Inc. (makers of Exparel), Heron Therapeutics, Inc. (Zynrelef), Vertex Pharmaceuticals (Journavx), and global injection specialists like Pfizer Inc. (Pfizer CentreOne)—operate as the primary downstream customers, purchasing raw upstream APIs and custom carrier vehicles to compound, sterilize, and package finished, hospital-ready analgesics. These finished clinical therapeutics are funneled downstream through Tier-1 pharmaceutical distributors including McKesson Corporation, AmerisourceBergen, and Cardinal Health. Ultimately, the vital final downstream enterprise end-users are acute care hospital networks (such as HCA Healthcare) and specialized ambulatory surgical centers (ASCs), which stock these fast-acting therapeutics in automated dispensing cabinets for surgical anesthesiologists and perioperative nursing teams to administer directly to patients entering post-anesthesia care units (PACU).

Key Questions Addressed in this Report

What is the 10-year outlook for the global Postoperative Pain Control Drug market?

What factors are driving Postoperative Pain Control Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Postoperative Pain Control Drug market opportunities vary by end market size?

How does Postoperative Pain Control Drug break out by Type, by Application?

This report presents a comprehensive overview of the global Postoperative Pain Control Drug market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Opioids
  • NSAIDs
  • Local Anesthetics
  • Tricyclic Antidepressants
  • Antiepileptic Drugs
  • Others

Segment by Dosage

  • Intravenous
  • Oral
  • Others

Segment by Action Area

  • Systemic
  • Regional

Segment by Application

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Postoperative Pain Control Drug market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital Pharmacies, Retail Pharmacies, Online Pharmacies evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Postoperative Pain Control Drug Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$5.12B
2025
Forecast
$7.9B
2032
CAGR
6.3%
2025–2032
영역들
5
global
Key companies
Mallinckrodt Pharmaceuticals (IE)Pfizer (US)Novartis (CH)Eli Lilly (US)Teva Pharmaceutical Industries (IL)Bayer (DE)Pacira BioSciences (US)Trevena (US)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
OpioidsNSAIDsLocal AnestheticsTricyclic AntidepressantsAntiepileptic DrugsOthers
By Application
Hospital PharmaciesRetail PharmaciesOnline PharmaciesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Opioids
  • 3.1.3 NSAIDs
  • 3.1.4 Local Anesthetics
  • 3.1.5 Tricyclic Antidepressants
  • 3.1.6 Antiepileptic Drugs
  • 3.1.7 Others
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital Pharmacies
  • 4.1.3 Retail Pharmacies
  • 4.1.4 Online Pharmacies
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Mallinckrodt Pharmaceuticals (IE)
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Pfizer (US)
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Novartis (CH)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Eli Lilly (US)
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Teva Pharmaceutical Industries (IL)
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Bayer (DE)
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Pacira BioSciences (US)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Trevena (US)
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Vertex Pharmaceuticals (US)
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Heron Therapeutics (US)
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Nanjing Delova Biotech (CN)
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Jiangsu Nhwa Pharmaceutical (CN)
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Postoperative Pain Control Drug market?
The global Postoperative Pain Control Drug market is estimated at US$ 5.12 billion in 2025 (base year) and is projected to reach US$ 7.74 billion by 2032.
How fast is the Postoperative Pain Control Drug market expected to grow?
The market is expected to grow at a CAGR of 6.3% from 2026 to 2032, expanding from US$ 5.12 billion in 2025 to US$ 7.74 billion in 2032, roughly 1.5 times its base-year value.
What does the Postoperative Pain Control Drug market cover?
Postoperative Pain Control Drugs encompass a specialized class of acute-use pharmaceuticals formulated to suppress nociceptive (pain-sensing) signaling pathways following surgical trauma. Historically dominated by central nervous system (CNS) mu-opioid receptor agonists like morphine, fentanyl, and hydromorphone, modern postoperative pain protocols have radically shifted toward multimodal analgesia.
How is the Postoperative Pain Control Drug market segmented by type?
By type, the market is segmented into Opioids, NSAIDs, Local Anesthetics, Tricyclic Antidepressants, Antiepileptic Drugs and Others.
What are the key applications of Postoperative Pain Control Drug?
Key applications covered include Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others.
Which companies are profiled in the Postoperative Pain Control Drug market report?
Key players profiled include Mallinckrodt Pharmaceuticals (IE), Pfizer (US), Novartis (CH), Eli Lilly (US), Teva Pharmaceutical Industries (IL), Bayer (DE), Pacira BioSciences (US) and Trevena (US), among 12 companies covered in total.
What geographies does the Postoperative Pain Control Drug market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Postoperative Pain Control Drug?
What factors are driving Postoperative Pain Control Drug market growth, globally and by region?
What are the main risks and barriers in the Postoperative Pain Control Drug market?
The supply chain for postoperative pain control drugs requires stringent chemical synthesis compliance, high-barrier sterile filling facilities, and specialized drug delivery carrier matrices.
Who should buy the Postoperative Pain Control Drug market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital Pharmacies, Retail Pharmacies and Online Pharmacies, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Postoperative Pain Control Drug market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.